(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.19%.
Zentalis Pharmaceuticals's earnings in 2026 is -$139,545,000.On average, 12 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$156,280,608, with the lowest ZNTL earnings forecast at -$167,869,957, and the highest ZNTL earnings forecast at -$100,089,828. On average, 12 Wall Street analysts forecast ZNTL's earnings for 2027 to be -$146,210,705, with the lowest ZNTL earnings forecast at -$193,858,193, and the highest ZNTL earnings forecast at -$95,574,497.
In 2028, ZNTL is forecast to generate -$123,913,572 in earnings, with the lowest earnings forecast at -$186,131,961 and the highest earnings forecast at -$75,255,510.